Search review questions

Motor fusion test · people with intermittent exotropia, aged 5 to 49 years

Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged 5 to 49 years

Quality of life measures Measured at 3 years using the IXTQ scores for children, parents, or parent proxies (i.e. parents' perception of their children's quality of life). Scores could range from 0 (worst quality of life) to 100 (best quality of l... · people with intermittent exotropia, aged 5 to 49 years

Motor alignment at near fixation Measured using the PACT at 6 months · people with intermittent exotropia, aged over 6 years

Stereoacuity at near · people with intermittent exotropia, aged over 6 years

Stereoacuity at distance Loss of ≥ 2 octaves near stereoacuity Measured using the Preschool Randot test 3 years after surgery · people with intermittent exotropia, aged over 6 years

Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged over 6 years

Quality of life measures Measured at 3 years using the IXTQ scores for children, parents, or parent proxies (i.e. parents' perception of their children's quality of life). Scores could range from 0 (worst quality of life) to 100 (best quality of l... · people with intermittent exotropia, aged over 6 years

Stereoacuity at distance · people with intermittent exotropia, aged 3 to < 11 years

Motor fusion test · people with intermittent exotropia, aged 3 to < 11 years

Adverse effects (at 12 months) · participants with primary angle‐closure glaucoma

Quality of life measures · participants with primary angle‐closure glaucoma

Progression of visual field loss · participants with primary angle closure glaucoma

Visual acuity (log MAR units) · participants with primary angle closure glaucoma

Adverse effects (at 6 months) · participants with primary angle closure glaucoma

Quality of life measures · participants with primary angle closure glaucoma

Progression of visual field loss (at 12 months) · participants with primary angle‐closure glaucoma

Gonioscopic findings · participants with primary angle‐closure glaucoma

Quality of life measures (at 12 months) · participants with primary angle‐closure glaucoma

Adverse effects · participants with primary angle‐closure glaucoma

Progression of visual field loss · participants with primary angle‐closure glaucoma

Disease progression · adults with PACS, PAC or PACG

Additional medications required · adults with PACS or PAC, and previous PI

Complications · adults with PACS or PAC, and previous PI

Further surgical or laser interventions · adults with PACS or PAC, and previous PI

Quality of life measures · adults with PACS or PAC, and previous PI

Quality of life measures · adults with PAC or PACG, and previous PI

Quality of life measures · adults with PACS, PAC or PACG

Disease progression · adults with PACS or PAC, and previous PI

Quality of life · people with simple rhegmatogenous retinal detachments

Failed trabeculectomy · patients with glaucoma

Visual acuity loss:defined as: loss of visual acuity equal to or greater than 0.3 LogMAR · patients with glaucoma

Quality of life, assessed by vision‐specific questionnaires · patients with glaucoma

Rate of visual field progression · participants 40 to 85 years of age with open‐angle glaucoma

Mean change in health‐related quality of life · participants 40 to 85 years of age with open‐angle glaucoma

Quality of life · people undergoing cataract surgery

Mean change in health‐related quality of life · people with open‐angle glaucoma

Rate of visual field progression or proportion of participants whose field loss progressed · people with open‐angle glaucoma

Mean pupillary diameter—at the time the surgeon performs capsulorhexis (mm) · patients undergoing cataract surgery

AE: participant‐reported ocular discomfort—week 1 · patients undergoing cataract surgery

AE: participant‐reported ocular discomfort—month 1 · patients undergoing cataract surgery

AE: vitreous loss—any time point during or after surgery · patients undergoing cataract surgery

Mean pupillary diameter—at the time the surgeon performs capsulorhexis (mm) · patients undergoing cataract surgery

AE: participant‐reported ocular discomfort—week 1 · patients undergoing cataract surgery

AE: participant‐reported ocular discomfort—month 1 · patients undergoing cataract surgery

Near vision · people with non‐exudative AMD (AREDS 2 to 4)

Low luminance deficit score · people with non‐exudative AMD (AREDS 2 to 4)

Reading speed · people with non‐exudative AMD (AREDS 2 to 4)

Quality of life · people with epiretinal membrane

Change in head posture ‐ not reported · infantile nystagmus syndrome